CD274 and non-small cell lung carcinoma: Marco et al. [54] pooled clinical data of 187 NSCLC patients treated with concurrent RT and PD-1/PD-L1 inhibitors at seven Italian centers between September 2015 and June 2019; the patients’ median follow-up duration was 23 months, whereas their median OS was 16.5 months.